ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,280.40
-0.06%
Dow Jones
40,415.44
0.32%
Brent Oil
81.44
-0.09%
Bitcoin
66,902.71
-1.04%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) News

URGN

UroGen Pharma (URGN)

UroGen Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:URGN
DateTimeSourceHeadlineSymbolCompany
07/09/20245:30PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:URGNUroGen Pharma Ltd
06/18/20245:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
06/18/20245:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:URGNUroGen Pharma Ltd
06/17/202410:51PMBusiness WireUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:URGNUroGen Pharma Ltd
06/17/20244:46PMGlobeNewswire Inc.UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:URGNUroGen Pharma Ltd
06/17/20244:19PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:URGNUroGen Pharma Ltd
06/13/202410:51AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
06/13/202410:45AMBusiness WireUroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
06/11/20241:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
06/11/20246:16AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
06/07/20248:00AMBusiness WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
06/06/20248:00AMBusiness WireUroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024NASDAQ:URGNUroGen Pharma Ltd
06/05/20248:00AMBusiness WireUroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceNASDAQ:URGNUroGen Pharma Ltd
06/03/20248:00AMBusiness WireUroGen Pharma Appoints David Lin as New Chief Commercial OfficerNASDAQ:URGNUroGen Pharma Ltd
05/22/20248:00AMBusiness WireUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:URGNUroGen Pharma Ltd
05/13/20248:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
05/13/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
05/13/20248:00AMBusiness WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
05/07/20248:00AMBusiness WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
05/05/202412:20PMBusiness WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
05/04/20243:20PMBusiness WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
05/04/202411:50AMBusiness WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
05/03/20248:00AMBusiness WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
04/17/202412:02PMBusiness WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
04/15/20248:00AMBusiness WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
04/03/20248:00AMBusiness WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
03/14/20248:00AMBusiness WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
03/08/20248:00AMBusiness WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
03/04/20248:00AMBusiness WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
03/04/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:URGN

Your Recent History

USOTC
ITUP
Interups (CE)
USOTC
IDVV
International Endeavors (PK)
NYSE
AMC
AMC Entertainment
USOTC
MGON
Megola (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
GRLT
Grillit (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
CNNA
Cann American (CE)
USOTC
NBRI
North Bay Resources (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
VPLM
Voip Pal Com (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved